Could a probiotic and laser ease menopause symptoms?
NCT ID NCT06978907
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a daily probiotic (Lactobacillus crispatus M247) combined with vaginal laser therapy can improve vaginal health and reduce symptoms like dryness, itching, and pain in menopausal women with atrophic vulvovaginitis. 75 women were split into two groups: one received laser alone, the other laser plus the probiotic. Researchers measured symptom changes and vaginal bacteria over three months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Lactobacillus crispatus M247 (Crispact®) probiotic
- What this could lead to
- If it works, this combination could offer a non-hormonal option to ease vaginal discomfort in menopausal women.
- What could go wrong
- This is a small, early study with only 75 participants. The probiotic may not significantly improve symptoms beyond laser alone, and individual results may vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
75 people
The number who actually took part.
- Started
-
Jul 2025
- Finished
-
Dec 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Menopausal women with no menstrual cycle for \>12 months. * Diagnosed with atrophic vulvovaginitis (VVA) and experiencing related symptoms (vaginal dryness, introital and profound dyspareunia, itching, burning, bleeding during intercourse). * Symptoms related to genitourinary syndrome of menopause (GSM), including urinary urgency, increased frequency, nocturia, recurrent cystitis, or post-coital cystitis. * Prior negative PAP test performed within one year of enrollment. * Women who are unresponsive to or dissatisfied with prior topical estrogen therapy or who have contraindications to local and/or systemic estrogen prescription. Exclusion Criteria: * Pregnancy or breastfeeding. * Presence of preneoplastic or neoplastic lesions of the cervix, vagina, or vulva. * Active genital and/or urinary tract infections. * Dermatological contraindications to laser therapy. * Ongoing systemic or local hormone therapy. * Neurological or psychiatric disorders. * Chronic systemic diseases of autoimmune or dysmetabolic nature.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atrophic vulvovaginitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital State of Republic of San Marino
San Mariano, 47893, Italy
-
Villa Margherita Clinic
Roma, 00161, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.